This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.
Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists. ... Rothwell, chairman of Emisphere. Novo’s GLP-1 agonist franchise also includes Ozempic
The once-weekly GLP-1 agonist has been available in the US since 2014, when it first gained FDA approval to improve glycaemic control in adults with type 2 diabetes. ... The new MACE approval could help Lilly in its fight for market share with other
The once-weekly injectable GLP-1 agonist has continued to offset declines of Novo’s older drugs, including the one-daily shot Victoza (liraglutide). ... It is the first oral alternative to injectable GLP-1 agonists, and has also been touted by Novo as
Potential to combat increasing competition and pricing pressures. Novo Nordisk has FDA approval for the first oral alternative to injectable GLP-1 agonists, which the company thinks could be a blockbuster ... product. The US regulator has approved the
Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.
Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... Trulicity's growth to date has stemmed largely from its once
More from news
Approximately 8 fully matching, plus 40 partially matching documents found.
Examples of this approach include developing statins for the treatment of dyslipidemia, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for hypertension, and glucagon-like peptide 1 ... 1) receptor agonists for
Upon interaction with the GLP-1 receptor, it stimulates the secretion of insulin in a glucose-dependent manner. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2,
Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...